Full-Time

Associate Director/Director

Regulatory Affairs

Confirmed live in the last 24 hours

Korro Bio

Korro Bio

51-200 employees

Develops RNA-based therapies for diseases

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Hybrid position at 60 first st, Cambridge, MA 02141.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor’s Degree, at minimum.
  • 8-10+ years of experience working in the pharmaceutical/ biopharmaceutical industry.
  • Experience with CDER and/or CBER required, and experience with global Health Authorities preferred.
  • Excellent communication and writing skills.
  • Hands-on, roll-up-your-sleeves approach.
  • Understanding of eCTD requirements, submission requirements, ESG requirements.
  • Experience with preparation of meeting requests and submissions, including the generation of a variety of content for submissions (eg, INTERACT, pre-IND, IND, Annual Reports, BLA/NDA, MAA).
  • Advanced Degree (MA/MS/MBA/PhD/PharmD) preferred.
  • Gene/Cell Therapy (AAV, Gene Editing, Anti-sense oligos) experience or expertise helpful.
  • Experience in a start-up or small company environment a plus!
Responsibilities
  • Provide Regulatory Strategy and also Operational guidance for programs and to project teams.
  • Manage regulatory aspects of programs including oversight and preparation of INDs, Briefing Books, Amendments, Annual Reports, Orphan Drug Designations, and eventual NDA/Marketing Application(s).
  • Act as the Regulatory Lead for assigned programs and projects and submissions to Global Health Authorities (FDA, EMA, etc.).
  • Facilitate the development of documentation for submission to regulatory authorities.
  • Collaborate with the Regulatory Operations/Publishing vendor when preparing submissions for submission via email, electronic Submission Gateway (ESG), and CTIS in Europe.
  • Lead project teams through meeting preparations for official meetings with Health Authorities (INTERACT, pre-IND, pre-CTA, End-of-Phase meetings, etc.).
  • Participate in and as needed lead interactions with FDA and other regulatory authorities for assigned projects to ensure acceptance, review, and approval of INDs, CTAs, NDAs/MAAs, amendments, and other submissions.
  • Develop and maintain relationships with regulatory authorities, internal departments, consultants, and other partners.
  • Articulate complex Regulatory issues to project teams and stakeholders to support development of Korro therapies.
  • Accountable for oversight of specific CROs and other vendors including vendor management.
  • Knowledgeable of the Regulations, Guidance, Laws, and ICH Guidelines.
  • Responsible for ensuring that Regulatory documents are prepared to industry and Health Authority standards.
  • Write and approve SOPs pertaining to Regulatory activities and documents.
  • Interact with other internal groups and lead project teams.
  • Make sound judgements taking into consideration patient safety, business risk, and compliance.
  • Manage and mentor any direct reports, as necessary.

Korro Bio develops RNA-based therapies aimed at treating serious diseases that currently lack effective treatments. The company uses RNA editing to make precise modifications at the RNA level, which allows for accurate changes to protein function. This method is seen as more precise and potentially safer than traditional gene editing techniques. Korro Bio focuses on research and development to create new therapies, which it can market independently or through partnerships with larger pharmaceutical companies. The company serves healthcare providers, hospitals, and patients, and collaborates with academic institutions to enhance its research. Korro Bio's goal is to make significant scientific advancements in medicine accessible to patients in need.

Company Stage

N/A

Total Funding

$383.7M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

4%

1 year growth

0%

2 year growth

17%
Simplify Jobs

Simplify's Take

What believers are saying

  • The $70 million raised for clinical trials and growth positions Korro Bio to advance its pipeline and achieve significant milestones.
  • The appointment of industry veterans like Dr. Rachel Meyers and Tim Pearson to the board strengthens the company's leadership and strategic direction.
  • Korro Bio's stock price surge of 171% in November indicates strong market confidence and potential for high returns.

What critics are saying

  • The biopharmaceutical market is highly competitive, and Korro Bio must continuously innovate to maintain its edge.
  • The success of RNA editing therapies is still uncertain and hinges on successful clinical trials and regulatory approvals.

What makes Korro Bio unique

  • Korro Bio's focus on RNA editing allows for precise single base modifications, offering a potentially safer and more accurate alternative to traditional gene editing and gene therapy.
  • The company's strategy of leveraging machine learning to enhance RNA delivery and platform development sets it apart from competitors.
  • Korro Bio's recent $70 million private placement and merger with Frequency Therapeutics provide substantial financial backing and expanded capabilities.

Help us improve and share your feedback! Did you find this helpful?